Radiopharm Theranostics Limited (ASX: RAD) - Share Price

- Current share price for RAD : $0.007

Radiopharm Theranostics Limited (RAD) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It operates as a clinical stage radiotherapeutics organisation developing a platform of radiopharmaceutical products for diagnostic and therapeutic use in areas of unmet medical need. The development pipeline consists of platform technologies that include peptides, small molecules, and monoclonal antibodies for cancer applications.

RAD General Information ⁺

ASX Code	RAD
Website	http://www.radiopharmtheranostics.com
Industry/Sector	Biotechnology
Market Cap ($M)	32
RAD Share Price	$0.007
Day High	$0.008
Day Low	$0.007
Last Close	$0.007
RAD Share Price Movement	- ( No change )

Prices as at 16:40, 29 Sep 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Radiopharm Theranostics Limited (RAD) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Radiopharm Theranostics Limited (RAD) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Radiopharm Theranostics Limited (RAD) price-sensitive announcements

RAD - RAD Doses First Patient in Second Cohort of BetaBart (RV-01)

Radiopharm Theranostics Limited announced the dosing of the first patient in the second co

Radiopharm Theranostics Limited (RAD)
26 Aug 2026 | 8:59 AM

RAD - RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial

Radiopharm Theranostics Limited announced the advancement of its 177Lu-RAD202 therapy to C

Radiopharm Theranostics Limited (RAD)
20 Aug 2026 | 8:51 AM

RAD - RAD to meet with US FDA to align on RAD 101 Phase 3 Trial

Radiopharm Theranostics Limited has announced an upcoming End-of-Phase 2 meeting with the

Radiopharm Theranostics Limited (RAD)
17 Aug 2026 | 9:02 AM

RAD - Quarterly Activities/Appendix 4C Cash Flow Report

Radiopharm Theranostics Limited, a clinical-stage biopharmaceutical company listed on the

Radiopharm Theranostics Limited (RAD)
31 Jul 2026 | 11:19 AM

Radiopharm Theranostics Limited (RAD) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$33	Change of Director's Interest Notices x 4	22 Sep 2026 2:13PM	$0.008	$0.007	fallen by 12.50%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$33	Notification regarding unquoted securities - RAD	17 Sep 2026 10:47AM	$0.008	$0.007	fallen by 6.67%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$33	RADOC New Class Options Range of Units and Top 20 Holders	17 Sep 2026 10:41AM	$0.008	$0.007	fallen by 6.67%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$33	Application for quotation of securities - RAD	17 Sep 2026 10:37AM	$0.008	$0.007	fallen by 6.67%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$33	Application for quotation of securities - RAD	17 Sep 2026 10:30AM	$0.008	$0.007	fallen by 6.67%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$33	Share purchase plan completed	17 Sep 2026 10:11AM	$0.008	$0.007	fallen by 6.67%

RAD Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2028F	C2	-$1.00	-31.00%	0.00%	0.0%
2027F	C2	-$1.50	-21.20%	0.00%	0.0%
2026A	-$58.62	-$1.80	17.20%	0.00%	0.0%

RAD Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F
CSL Limited (CSL)	$84,916M	0.7309	-0.4435	0.0545	10.9624	19.6981	18.6794	2.40%	2.35%	2.43%
Mesoblast Limited (MSB)	$2,805M	-0.4380	0.0000	0.0000	0.0000	0.0000	342.8571	0.00%	0.00%	0.00%
PYC Therapeutics Limited (PYC)	$2,773M	-0.3971	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Radiopharm Theranostics Limited (RAD)	$38M	0.1720	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,404M	-1.3893	0.0000	-0.2773	0.0000	175.6906	243.1193	0.00%	0.00%	0.00%

RAD Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	1.00	0.00
Market	0.34	13.70	1.16	0.78
Sector	0.65	30.70	2.70	1.49

RAD Directors

Name	Position	Start Date
Mr Riccardo Canevari	Chief Executive Officer, Managing Director	13 Sep 2021
Mr Paul Alex Hopper	Executive Chairman, Founder, Executive Director	11 Feb 2021
Mr Ian Turner	Non-Executive Director	1 Apr 2021
Ms Hester Larkin	Non-Executive Director	3 Feb 2022
Mr Noel Donnelly	Non-Executive Director	1 Oct 2024
Mr Bruce Goodwin	Non-Executive Director	19 Nov 2025

Radiopharm Theranostics Limited (RAD) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
17 Sep 2026	TURNER, Ian	Issued	Direct Shares	1,222,222	$0.009	$10,999.998
17 Sep 2026	TURNER, Ian	Issued	Indirect Shares	1,555,556	$0.009	$14,000.004
17 Sep 2026	GOODWIN, Bruce	Issued	Indirect Shares	2,777,778	$0.009	$25,000.000

See all changes in directors' interest & trades for Radiopharm Theranostics Limited (RAD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RAD Management

Name	Position
Dimitris Voliotis	Chief Medical Officer
Amritha Sushil	Joint Company Secretary
Nathan Kim -liung Jong	Joint Company Secretary

RAD Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Radiopharm Theranostics Limited (RAD). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
282,958,513 (12.12%)	Lantheus Omega, LLC
145,362,288 (7.30%)	Regal Funds Management Pty Ltd
149,221,428 (6.90%)	Paul Hopper
174,583,414 (6.90%)	JPmorgan Chase & Co. and its affiliates

RAD Calendar of Events

Date	Event
27 August 2027	Report (Prelim)
26 February 2027	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us